BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pérez-Caballero D, González-Rubio C, Gallardo ME, Vera M, López-Trascasa M, Rodríguez de Córdoba S, Sánchez-Corral P. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 2001;68:478-84. [PMID: 11170895 DOI: 10.1086/318201] [Cited by in Crossref: 211] [Cited by in F6Publishing: 195] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP. Advances in understanding of pathogenesis of aHUS and HELLP. British Journal of Haematology 2008;143:336-48. [DOI: 10.1111/j.1365-2141.2008.07324.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
2 Johnson S, Waters A. Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome? Immunobiology 2012;217:235-43. [PMID: 21852019 DOI: 10.1016/j.imbio.2011.07.022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
3 Tchepeleva SN, Thurman JM, Ruff K, Perkins SJ, Morel L, Boackle SA. An allelic variant of Crry in the murine Sle1c lupus susceptibility interval is not impaired in its ability to regulate complement activation. J Immunol 2010;185:2331-9. [PMID: 20660348 DOI: 10.4049/jimmunol.1000783] [Reference Citation Analysis]
4 Ariceta G. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way. Pediatr Nephrol 2019;34:943-9. [PMID: 30693384 DOI: 10.1007/s00467-019-4192-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
5 Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F, Caprioli J, Brioschi S, Scheiflinger F, Remuzzi G; International Registry of Recurrent and Familial HUS/TTP. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 2005;16:1177-83. [PMID: 15800115 DOI: 10.1681/ASN.2005010086] [Cited by in Crossref: 103] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
6 Noris M, Remuzzi G. Genetics and Genetic Testing in Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Seminars in Nephrology 2010;30:395-408. [DOI: 10.1016/j.semnephrol.2010.06.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
7 Pangburn MK. Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome. J Immunol 2002;169:4702-6. [PMID: 12391176 DOI: 10.4049/jimmunol.169.9.4702] [Cited by in Crossref: 96] [Cited by in F6Publishing: 88] [Article Influence: 4.8] [Reference Citation Analysis]
8 Anoosha P, Sakthivel R, Michael Gromiha M. Exploring preferred amino acid mutations in cancer genes: Applications to identify potential drug targets. Biochim Biophys Acta 2016;1862:155-65. [PMID: 26581171 DOI: 10.1016/j.bbadis.2015.11.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
9 Jokiranta TS, Jaakola VP, Lehtinen MJ, Pärepalo M, Meri S, Goldman A. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J 2006;25:1784-94. [PMID: 16601698 DOI: 10.1038/sj.emboj.7601052] [Cited by in Crossref: 126] [Cited by in F6Publishing: 118] [Article Influence: 7.9] [Reference Citation Analysis]
10 Goodship TH, Liszewski M, Kemp EJ, Richards A, Atkinson JP. Mutations in CD46, a complement regulatory protein, predispose to atypical HUS. Trends in Molecular Medicine 2004;10:226-31. [DOI: 10.1016/j.molmed.2004.03.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
11 Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, Gamba S, Brioschi S, Daina E, Remuzzi G. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet. 2003;12:3385-3395. [PMID: 14583443 DOI: 10.1093/hmg/ddg363] [Cited by in Crossref: 230] [Cited by in F6Publishing: 209] [Article Influence: 12.1] [Reference Citation Analysis]
12 Kavanagh D, Kemp EJ, Richards A, Burgess RM, Mayland E, Goodship JA, Goodship TH. Does complement factor B have a role in the pathogenesis of atypical HUS? Molecular Immunology 2006;43:856-9. [DOI: 10.1016/j.molimm.2005.06.041] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
13 Clemenza L, Dieli F, Cicardi M, Salerno A. Research on complement: old issues revisited and a novel sphere of influence. Trends in Immunology 2003;24:292-5. [DOI: 10.1016/s1471-4906(03)00118-2] [Cited by in Crossref: 9] [Article Influence: 0.5] [Reference Citation Analysis]
14 Schmidt CQ, Herbert AP, Hocking HG, Uhrín D, Barlow PN. Translational mini-review series on complement factor H: structural and functional correlations for factor H. Clin Exp Immunol. 2008;151:14-24. [PMID: 18081691 DOI: 10.1111/j.1365-2249.2007.03553.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 7.2] [Reference Citation Analysis]
15 Ersoy Dursun F, Yesil G, Sasak G, Dursin H. Familial Atypical Hemolytic Uremic Syndrome with Positive p.S1191L (c.3572C>T) Mutation on the CFH Gene: A Single-center Experience. Balkan J Med Genet 2021;24:81-8. [PMID: 34447663 DOI: 10.2478/bjmg-2021-0007] [Reference Citation Analysis]
16 Tortajada A, Yébenes H, Abarrategui-Garrido C, Anter J, García-Fernández JM, Martínez-Barricarte R, Alba-Domínguez M, Malik TH, Bedoya R, Cabrera Pérez R. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest. 2013;123:2434-2446. [PMID: 23728178 DOI: 10.1172/jci68280] [Cited by in Crossref: 140] [Cited by in F6Publishing: 82] [Article Influence: 15.6] [Reference Citation Analysis]
17 Qi P, Wu B, Guo B, Zhang C, Xu K. The complement factor H (CFH) and its related protein 2 (CFHR2) mediating immune response in large yellow croaker Larimichthys crocea. Dev Comp Immunol 2018;84:241-9. [PMID: 29496498 DOI: 10.1016/j.dci.2018.02.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
18 Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Carreras Berges L, López-Trascasa M, Sánchez-Corral P, Rodríguez de Córdoba S. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005;14:703-12. [PMID: 15661753 DOI: 10.1093/hmg/ddi066] [Cited by in Crossref: 207] [Cited by in F6Publishing: 191] [Article Influence: 12.2] [Reference Citation Analysis]
19 Blatt AZ, Pathan S, Ferreira VP. Properdin: a tightly regulated critical inflammatory modulator. Immunol Rev 2016;274:172-90. [PMID: 27782331 DOI: 10.1111/imr.12466] [Cited by in Crossref: 64] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
20 Cruzado JM, de Córdoba SR, Melilli E, Bestard O, Rama I, Sánchez-Corral P, López-Trascasa M, Navarro I, Torras J, Gomà M, Grinyó JM. Successful renal transplantation in a patient with atypical hemolytic uremic syndrome carrying mutations in both factor I and MCP. Am J Transplant 2009;9:1477-83. [PMID: 19459807 DOI: 10.1111/j.1600-6143.2009.02647.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
21 Johnson S, Taylor CM. Hemolytic Uremic Syndrome. In: Avner E, Harmon W, Niaudet P, Yoshikawa N, editors. Pediatric Nephrology. Berlin: Springer Berlin Heidelberg; 2009. pp. 1155-80. [DOI: 10.1007/978-3-540-76341-3_48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Saland JM, Ruggenenti P, Remuzzi G. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2009;20:940-949. [PMID: 19092117 DOI: 10.1681/asn.2008080906] [Cited by in Crossref: 127] [Cited by in F6Publishing: 51] [Article Influence: 9.1] [Reference Citation Analysis]
23 Ueda Y, Miwa T, Ito D, Kim H, Sato S, Gullipalli D, Zhou L, Golla M, Song D, Dunaief JL, Palmer MB, Song WC. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation. Kidney Int 2019;96:67-79. [PMID: 30910380 DOI: 10.1016/j.kint.2019.01.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
24 Ferreira VP, Herbert AP, Hocking HG, Barlow PN, Pangburn MK. Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces. J Immunol 2006;177:6308-16. [PMID: 17056561 DOI: 10.4049/jimmunol.177.9.6308] [Cited by in Crossref: 115] [Cited by in F6Publishing: 112] [Article Influence: 7.2] [Reference Citation Analysis]
25 Cheng ZZ, Hellwage J, Seeberger H, Zipfel PF, Meri S, Jokiranta TS. Comparison of surface recognition and C3b binding properties of mouse and human complement factor H. Mol Immunol 2006;43:972-9. [PMID: 16023208 DOI: 10.1016/j.molimm.2005.05.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
26 de Jorge EG, Macor P, Paixão-Cavalcante D, Rose KL, Tedesco F, Cook HT, Botto M, Pickering MC. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol 2011;22:137-45. [PMID: 21148255 DOI: 10.1681/ASN.2010050451] [Cited by in Crossref: 85] [Cited by in F6Publishing: 36] [Article Influence: 7.1] [Reference Citation Analysis]
27 Kim JJ, Goodship THJ, Tizard J, Inward C. Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations. Pediatr Nephrol 2011;26:2073-6. [DOI: 10.1007/s00467-011-1944-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
28 Barlow P, Soares D. Complement Control Protein Modules in the Regulators of Complement Activation. In: Morikis D, Lambris J, editors. Structural Biology of the Complement System. CRC Press; 2005. pp. 19-62. [DOI: 10.1201/9780849350368.ch2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
29 Tu Z, Li Q, Bu H, Lin F. Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells Dev. 2010;19:1803-1809. [PMID: 20163251 DOI: 10.1089/scd.2009.0418] [Cited by in Crossref: 84] [Cited by in F6Publishing: 82] [Article Influence: 7.0] [Reference Citation Analysis]
30 Jokiranta TS, Zipfel PF, Fremeaux-bacchi V, Taylor CM, Goodship TJ, Noris M. Where next with atypical hemolytic uremic syndrome? Molecular Immunology 2007;44:3889-900. [DOI: 10.1016/j.molimm.2007.06.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
31 Zhang Y, Meyer NC, Wang K, Nishimura C, Frees K, Jones M, Katz LM, Sethi S, Smith RJ. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 2012;7:265-74. [PMID: 22223606 DOI: 10.2215/CJN.07900811] [Cited by in Crossref: 128] [Cited by in F6Publishing: 70] [Article Influence: 12.8] [Reference Citation Analysis]
32 Taylor C. Complement factor H and the haemolytic uraemic syndrome. The Lancet 2001;358:1200-2. [DOI: 10.1016/s0140-6736(01)06339-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
33 Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001;60:831-846. [PMID: 11532079 DOI: 10.1046/j.1523-1755.2001.060003831.x] [Cited by in Crossref: 304] [Cited by in F6Publishing: 228] [Article Influence: 14.5] [Reference Citation Analysis]
34 Mohlin FC, Mercier E, Fremeaux-Bacchi V, Liszewski MK, Atkinson JP, Gris JC, Blom AM. Analysis of genes coding for CD46, CD55, and C4b-binding protein in patients with idiopathic, recurrent, spontaneous pregnancy loss. Eur J Immunol 2013;43:1617-29. [PMID: 23508668 DOI: 10.1002/eji.201243196] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
35 Zipfel PF, Lauer N, Skerka C. The Role of Complement in AMD. In: Lambris JD, Adamis AP, editors. Inflammation and Retinal Disease: Complement Biology and Pathology. New York: Springer; 2010. pp. 9-24. [DOI: 10.1007/978-1-4419-5635-4_2] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 6.0] [Reference Citation Analysis]
36 Berra S, Clivio A. Rapid isolation of pure Complement Factor H from serum for functional studies by the use of a monoclonal antibody that discriminates FH from all the other isoforms. Mol Immunol 2016;72:65-73. [PMID: 26972487 DOI: 10.1016/j.molimm.2016.03.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Medjeral-Thomas N, Pickering MC. The complement factor H-related proteins. Immunol Rev. 2016;274:191-201. [PMID: 27782332 DOI: 10.1111/imr.12477] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
38 Saunders RE, Goodship TH, Zipfel PF, Perkins SJ. An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations. Hum Mutat 2006;27:21-30. [PMID: 16281287 DOI: 10.1002/humu.20268] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 4.1] [Reference Citation Analysis]
39 Blom AM, Bergström F, Edey M, Diaz-Torres M, Kavanagh D, Lampe A, Goodship JA, Strain L, Moghal N, McHugh M, Inward C, Tomson C, Frémeaux-Bacchi V, Villoutreix BO, Goodship TH. A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. J Immunol 2008;180:6385-91. [PMID: 18424762 DOI: 10.4049/jimmunol.180.9.6385] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
40 Zipfel PF, Neumann HP, J??zsi M. Genetic screening in haemolytic uraemic syndrome: . Current Opinion in Nephrology and Hypertension 2003;12:653-7. [DOI: 10.1097/00041552-200311000-00014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
41 Gaut JP, Jain S, Pfeifer JD, Vigh-Conrad KA, Corliss M, Sharma MK, Heusel JW, Cottrell CE. Routine use of clinical exome-based next-generation sequencing for evaluation of patients with thrombotic microangiopathies. Mod Pathol 2017;30:1739-47. [PMID: 28752844 DOI: 10.1038/modpathol.2017.90] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
42 Herbert AP, Soares DC, Pangburn MK, Barlow PN. Disease-associated sequence variations in factor H: a structural biology approach. Adv Exp Med Biol 2006;586:313-27. [PMID: 16893081 DOI: 10.1007/0-387-34134-X_21] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Kavanagh D, Richards A, Fremeaux-Bacchi V, Noris M, Goodship T, Remuzzi G, Atkinson JP. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2007;2:591-6. [PMID: 17699467 DOI: 10.2215/CJN.03270906] [Cited by in Crossref: 44] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
44 Sánchez-Corral P, Melgosa M. Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome. Br J Haematol 2010;150:529-42. [PMID: 20629662 DOI: 10.1111/j.1365-2141.2010.08295.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
45 Mollnes TE, Jokiranta TS, Truedsson L, Nilsson B, Rodriguez de Cordoba S, Kirschfink M. Complement analysis in the 21st century. Molecular Immunology 2007;44:3838-49. [DOI: 10.1016/j.molimm.2007.06.150] [Cited by in Crossref: 103] [Cited by in F6Publishing: 80] [Article Influence: 6.9] [Reference Citation Analysis]
46 Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Müslümanoğlu MH, Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship TH. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003;100:12966-71. [PMID: 14566051 DOI: 10.1073/pnas.2135497100] [Cited by in Crossref: 310] [Cited by in F6Publishing: 269] [Article Influence: 16.3] [Reference Citation Analysis]
47 Abarrategui-Garrido C, Martínez-Barricarte R, López-Trascasa M, de Córdoba SR, Sánchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009;114:4261-71. [PMID: 19745068 DOI: 10.1182/blood-2009-05-223834] [Cited by in Crossref: 145] [Cited by in F6Publishing: 133] [Article Influence: 11.2] [Reference Citation Analysis]
48 García-Fernández J, Vilches-Arroyo S, Olavarrieta L, Pérez-Pérez J, Rodríguez de Córdoba S. Detection of Genetic Rearrangements in the Regulators of Complement Activation RCA Cluster by High-Throughput Sequencing and MLPA. Methods Mol Biol 2021;2227:159-78. [PMID: 33847941 DOI: 10.1007/978-1-0716-1016-9_16] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008;23:1957-72. [PMID: 18594873 DOI: 10.1007/s00467-008-0872-4] [Cited by in Crossref: 135] [Cited by in F6Publishing: 109] [Article Influence: 9.6] [Reference Citation Analysis]
50 Richards A, Kavanagh D, Atkinson JP. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. Adv Immunol 2007;96:141-77. [PMID: 17981206 DOI: 10.1016/S0065-2776(07)96004-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
51 Martínez-Barricarte R, Heurich M, López-Perrote A, Tortajada A, Pinto S, López-Trascasa M, Sánchez-Corral P, Morgan BP, Llorca O, Harris CL, Rodríguez de Córdoba S. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Mol Immunol 2015;66:263-73. [PMID: 25879158 DOI: 10.1016/j.molimm.2015.03.248] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
52 Servais A, Frémeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, Grünfeld JP, Lesavre P, Noël LH, Fakhouri F. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007;44:193-9. [PMID: 17018561 DOI: 10.1136/jmg.2006.045328] [Cited by in Crossref: 211] [Cited by in F6Publishing: 187] [Article Influence: 13.2] [Reference Citation Analysis]
53 Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, Diaz-Torres ML, Sampson A, Mead P, Webb M. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med. 2006;3:e431. [PMID: 17076561 DOI: 10.1371/journal.pmed.0030431] [Cited by in Crossref: 145] [Cited by in F6Publishing: 137] [Article Influence: 9.7] [Reference Citation Analysis]
54 Lumbreras J, Subias M, Espinosa N, Ferrer JM, Arjona E, Rodríguez de Córdoba S. The Relevance of the MCP Risk Polymorphism to the Outcome of aHUS Associated With C3 Mutations. A Case Report. Front Immunol 2020;11:1348. [PMID: 32765494 DOI: 10.3389/fimmu.2020.01348] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Hakobyan S, Tortajada A, Harris CL, de Córdoba SR, Morgan BP. Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome. Kidney Int 2010;78:782-8. [PMID: 20703214 DOI: 10.1038/ki.2010.275] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
56 Sánchez Chinchilla D, Pinto S, Hoppe B, Adragna M, Lopez L, Justa Roldan ML, Peña A, Lopez Trascasa M, Sánchez-Corral P, Rodríguez de Córdoba S. Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2014;9:1611-9. [PMID: 25135762 DOI: 10.2215/CJN.01640214] [Cited by in Crossref: 51] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
57 Jalanko H, Peltonen S, Koskinen A, Puntila J, Isoniemi H, Holmberg C, Pinomäki A, Armstrong E, Koivusalo A, Tukiainen E, Mäkisalo H, Saland J, Remuzzi G, de Cordoba S, Lassila R, Meri S, Jokiranta TS. Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. Am J Transplant 2008;8:216-21. [PMID: 17973958 DOI: 10.1111/j.1600-6143.2007.02029.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 35] [Article Influence: 0.1] [Reference Citation Analysis]
58 Recalde S, Tortajada A, Subias M, Anter J, Blasco M, Maranta R, Coco R, Pinto S, Noris M, García-Layana A, Rodríguez de Córdoba S. Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases. J Am Soc Nephrol 2016;27:1305-11. [PMID: 26376859 DOI: 10.1681/ASN.2015050580] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
59 Cserhalmi M, Papp A, Brandus B, Uzonyi B, Józsi M. Regulation of regulators: Role of the complement factor H-related proteins. Semin Immunol 2019;45:101341. [PMID: 31757608 DOI: 10.1016/j.smim.2019.101341] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
60 Cho HY, Lee BS, Moon KC, Ha IS, Cheong HI, Choi Y. Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate. Pediatr Nephrol 2007;22:874-80. [PMID: 17295030 DOI: 10.1007/s00467-007-0438-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
61 Hyvärinen S, Meri S, Jokiranta TS. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome. Blood 2016;127:2701-10. [PMID: 27006390 DOI: 10.1182/blood-2015-11-680009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
62 Frémeaux-Bacchi V, Sellier-Leclerc AL, Vieira-Martins P, Limou S, Kwon T, Lahoche A, Novo R, Llanas B, Nobili F, Roussey G, Cailliez M, Ulinski T, Deschênes G, Alberti C, Weill FX, Mariani P, Loirat C. Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study. Clin J Am Soc Nephrol 2019;14:364-77. [PMID: 30674459 DOI: 10.2215/CJN.05830518] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
63 Richards A, Kathryn Liszewski M, Kavanagh D, Fang CJ, Moulton E, Fremeaux-Bacchi V, Remuzzi G, Noris M, Goodship TH, Atkinson JP. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol 2007;44:111-22. [PMID: 16882452 DOI: 10.1016/j.molimm.2006.07.004] [Cited by in Crossref: 97] [Cited by in F6Publishing: 87] [Article Influence: 6.1] [Reference Citation Analysis]
64 Donne RL, Abbs I, Barany P, Elinder CG, Little M, Conlon P, Goodship TH. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. Am J Kidney Dis 2002;40:E22. [PMID: 12460067 DOI: 10.1053/ajkd.2002.36938] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
65 Monteferrante G, Brioschi S, Caprioli J, Pianetti G, Bettinaglio P, Bresin E, Remuzzi G, Noris M. Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. Molecular Immunology 2007;44:1704-8. [DOI: 10.1016/j.molimm.2006.08.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
66 Liszewski MK, Leung MK, Schraml B, Goodship TH, Atkinson JP. Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol 2007;44:1559-68. [PMID: 17027083 DOI: 10.1016/j.molimm.2006.08.024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
67 Marini SC, Gomes M, Guilherme R, Carda JP, Pinto CS, Fidalgo T, Ribeiro ML. Atypical hemolytic-uremic syndrome: recurrent phenotypic expression of a patient with MCP gene mutation combined with risk haplotypes. Blood Coagul Fibrinolysis 2019;30:68-70. [PMID: 30676336 DOI: 10.1097/MBC.0000000000000793] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Caprioli J, Peng L, Remuzzi G. The hemolytic uremic syndromes: . Current Opinion in Critical Care 2005;11:487-92. [DOI: 10.1097/01.ccx.0000176688.10810.30] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
69 Boon CJ, van de Kar NC, Klevering BJ, Keunen JE, Cremers FP, Klaver CC, Hoyng CB, Daha MR, den Hollander AI. The spectrum of phenotypes caused by variants in the CFH gene. Molecular Immunology 2009;46:1573-94. [DOI: 10.1016/j.molimm.2009.02.013] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
70 Sánchez-Corral P, Pérez-Caballero D, Huarte O, Simckes AM, Goicoechea E, López-Trascasa M, de Córdoba SR. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet 2002;71:1285-95. [PMID: 12424708 DOI: 10.1086/344515] [Cited by in Crossref: 157] [Cited by in F6Publishing: 149] [Article Influence: 7.9] [Reference Citation Analysis]
71 Thompson CL, Klein BE, Klein R, Xu Z, Capriotti J, Joshi T, Leontiev D, Lee KE, Elston RC, Iyengar SK. Complement factor H and hemicentin-1 in age-related macular degeneration and renal phenotypes. Human Molecular Genetics 2007;16:2135-48. [DOI: 10.1093/hmg/ddm164] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
72 de Cordoba SR, Tortajada A, Harris CL, Morgan BP. Complement dysregulation and disease: from genes and proteins to diagnostics and drugs. Immunobiology. 2012;217:1034-1046. [PMID: 22964229 DOI: 10.1016/j.imbio.2012.07.021] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 8.9] [Reference Citation Analysis]
73 Gotoh N, Yamada R, Hiratani H, Renault V, Kuroiwa S, Monet M, Toyoda S, Chida S, Mandai M, Otani A, Yoshimura N, Matsuda F. No association between complement factor H gene polymorphism and exudative age-related macular degeneration in Japanese. Hum Genet 2006;120:139-43. [DOI: 10.1007/s00439-006-0187-0] [Cited by in Crossref: 102] [Cited by in F6Publishing: 98] [Article Influence: 6.4] [Reference Citation Analysis]
74 Bíró A, Prohászka Z, Füst G, Blaskó B. Determination of complement factor H functional polymorphisms (V62I, Y402H, and E936D) using sequence-specific primer PCR and restriction fragment length polymorphisms. Mol Diagn Ther 2006;10:303-10. [PMID: 17022693 DOI: 10.1007/BF03256205] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
75 Bernabéu-Herrero ME, Jiménez-Alcázar M, Anter J, Pinto S, Sánchez Chinchilla D, Garrido S, López-Trascasa M, Rodríguez de Córdoba S, Sánchez-Corral P. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. Mol Immunol 2015;67:276-86. [PMID: 26163426 DOI: 10.1016/j.molimm.2015.06.021] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
76 Frémeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Lhotta K. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood. 2008;112:4948-4952. [PMID: 18796626 DOI: 10.1182/blood-2008-01-133702] [Cited by in Crossref: 293] [Cited by in F6Publishing: 258] [Article Influence: 20.9] [Reference Citation Analysis]
77 Kavanagh D, Pappworth IY, Anderson H, Hayes CM, Moore I, Hunze EM, Bennaceur K, Roversi P, Lea S, Strain L. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? Clin J Am Soc Nephrol. 2012;7:417-426. [PMID: 22223611 DOI: 10.2215/cjn.05750611] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
78 Sallée M, Daniel L, Piercecchi MD, Jaubert D, Fremeaux-Bacchi V, Berland Y, Burtey S. Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrol Dial Transplant 2010;25:2028-32. [PMID: 20305136 DOI: 10.1093/ndt/gfq160] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
79 Zipfel PF, Heinen S, Józsi M, Skerka C. Complement and diseases: Defective alternative pathway control results in kidney and eye diseases. Molecular Immunology 2006;43:97-106. [DOI: 10.1016/j.molimm.2005.06.015] [Cited by in Crossref: 156] [Cited by in F6Publishing: 138] [Article Influence: 9.8] [Reference Citation Analysis]
80 Pechtl IC, Kavanagh D, McIntosh N, Harris CL, Barlow PN. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem 2011;286:11082-90. [PMID: 21270465 DOI: 10.1074/jbc.M110.211839] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
81 Lehtinen MJ, Rops AL, Isenman DE, van der Vlag J, Jokiranta TS. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem 2009;284:15650-8. [PMID: 19351878 DOI: 10.1074/jbc.M900814200] [Cited by in Crossref: 74] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
82 Zipfel PF. Hemolytic uremic syndrome: how do factor H mutants mediate endothelial damage? Trends in Immunology 2001;22:345-8. [DOI: 10.1016/s1471-4906(01)01972-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
83 Kavanagh D, Goodship TH. Update on evaluating complement in hemolytic uremic syndrome. Curr Opin Nephrol Hypertens. 2007;16:565-571. [PMID: 18089972 DOI: 10.1097/mnh.0b013e3282f0872f] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
84 Józsi M, Tortajada A, Uzonyi B, Goicoechea de Jorge E, Rodríguez de Córdoba S. Factor H-related proteins determine complement-activating surfaces. Trends in Immunology 2015;36:374-84. [DOI: 10.1016/j.it.2015.04.008] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 12.7] [Reference Citation Analysis]
85 Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16:1035-1050. [PMID: 15728781 DOI: 10.1681/asn.2004100861] [Cited by in Crossref: 333] [Cited by in F6Publishing: 108] [Article Influence: 19.6] [Reference Citation Analysis]
86 Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, de Córdoba SR. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med. 2007;204:1249-1256. [PMID: 17517971 DOI: 10.1084/jem.20070301] [Cited by in Crossref: 201] [Cited by in F6Publishing: 180] [Article Influence: 13.4] [Reference Citation Analysis]
87 Lapeyraque AL, Wagner E, Phan V, Clermont MJ, Merouani A, Frémeaux-Bacchi V, Goodship TH, Robitaille P. Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations. Pediatr Nephrol 2008;23:1363-6. [PMID: 18425537 DOI: 10.1007/s00467-008-0803-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
88 Kavanagh D, Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol 2010;25:2431-42. [PMID: 20526633 DOI: 10.1007/s00467-010-1555-5] [Cited by in Crossref: 117] [Cited by in F6Publishing: 98] [Article Influence: 9.8] [Reference Citation Analysis]
89 Szarvas N, Szilágyi Á, Csuka D, Takács B, Rusai K, Müller T, Arbeiter K, Réti M, Haris Á, Wagner L, Török S, Kelen K, Szabó AJ, Reusz GS, Morgan BP, Prohászka Z. Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome. Molecular Immunology 2016;71:10-22. [DOI: 10.1016/j.molimm.2016.01.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
90 Poolpol K, Gadner B, Neururer S, Mellmann A, Karch H, Orth D, Würzner R. Do complement factor H 402Y and C7 M allotypes predispose to (typical) haemolytic uraemic syndrome? Int J Immunogenet 2011;38:383-7. [PMID: 21649859 DOI: 10.1111/j.1744-313X.2011.01017.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
91 Johnson S, Taylor CM. What's new in haemolytic uraemic syndrome? Eur J Pediatr 2008;167:965-71. [PMID: 18575887 DOI: 10.1007/s00431-008-0745-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
92 Ueda Y, Mohammed I, Song D, Gullipalli D, Zhou L, Sato S, Wang Y, Gupta S, Cheng Z, Wang H, Bao J, Mao Y, Brass L, Zheng XL, Miwa T, Palmer M, Dunaief J, Song WC. Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation. Blood 2017;129:1184-96. [PMID: 28057640 DOI: 10.1182/blood-2016-07-728253] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
93 Skerka C, Józsi M. Role of complement and Factor H in hemolytic uremic syndrome. In: Zipfel PF, editor. Complement and Kidney Disease. Basel: Birkhäuser-Verlag; 2006. pp. 85-109. [DOI: 10.1007/3-7643-7428-4_6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
94 Thielen AJF, Zeerleder S, Wouters D. Consequences of dysregulated complement regulators on red blood cells. Blood Rev 2018;32:280-8. [PMID: 29397262 DOI: 10.1016/j.blre.2018.01.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
95 Ruggenenti P. Post-transplant hemolytic-uremic syndrome. Kidney Int. 2002;62:1093-1104. [PMID: 12164897 DOI: 10.1046/j.1523-1755.2002.00543.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
96 Koskinen AR, Cheng ZZ, Pickering MC, Kairemo K, Meri T, Cook HT, Meri S, Jokiranta TS. Distribution of exogenous complement factor H in mice in vivo. Scand J Immunol 2018;88:e12671. [PMID: 29706017 DOI: 10.1111/sji.12671] [Reference Citation Analysis]
97 Vaziri-sani F, Holmberg L, Sjöholm A, Kristoffersson A, Manea M, Frémeaux-bacchi V, Fehrman-ekholm I, Raafat R, Karpman D. Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney International 2006;69:981-8. [DOI: 10.1038/sj.ki.5000155] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 4.7] [Reference Citation Analysis]
98 Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Seminars in Hematology 2004;41:68-74. [DOI: 10.1053/j.seminhematol.2003.10.009] [Cited by in Crossref: 80] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
99 Ferreira VP, Pangburn MK, Cortés C. Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol 2010;47:2187-97. [PMID: 20580090 DOI: 10.1016/j.molimm.2010.05.007] [Cited by in Crossref: 239] [Cited by in F6Publishing: 213] [Article Influence: 19.9] [Reference Citation Analysis]
100 Geerlings MJ, de Jong EK, den Hollander AI. The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment. Mol Immunol 2017;84:65-76. [PMID: 27939104 DOI: 10.1016/j.molimm.2016.11.016] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 12.7] [Reference Citation Analysis]
101 Licht C, Weyersberg A, Heinen S, Stapenhorst L, Devenge J, Beck B, Waldherr R, Kirschfink M, Zipfel PF, Hoppe B. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005;45:415-21. [PMID: 15685522 DOI: 10.1053/j.ajkd.2004.10.018] [Cited by in Crossref: 94] [Cited by in F6Publishing: 71] [Article Influence: 5.5] [Reference Citation Analysis]
102 Fraczek LA, Martin CB, Martin BK. c-Jun and c-Fos regulate the complement factor H promoter in murine astrocytes. Mol Immunol 2011;49:201-10. [PMID: 21920606 DOI: 10.1016/j.molimm.2011.08.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
103 Song D, Ueda Y, Bhuyan R, Mohammed I, Miwa T, Gullipali D, Kim H, Zhou L, Song Y, Schultz H, Bargoud A, Dunaief JL, Song WC. Complement Factor H Mutation W1206R Causes Retinal Thrombosis and Ischemic Retinopathy in Mice. Am J Pathol 2019;189:826-38. [PMID: 30711487 DOI: 10.1016/j.ajpath.2019.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
104 Hyvärinen S, Uchida K, Varjosalo M, Jokela R, Jokiranta TS. Recognition of malondialdehyde-modified proteins by the C terminus of complement factor H is mediated via the polyanion binding site and impaired by mutations found in atypical hemolytic uremic syndrome. J Biol Chem 2014;289:4295-306. [PMID: 24344133 DOI: 10.1074/jbc.M113.527416] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
105 Leban N, Abarrategui-garrido C, Fariza-requejo E, Amiñoso-carbonero C, Pinto S, Chibani JB, Khelil AH, Sánchez-corral P. Factor H and CFHR1 polymorphisms associated with atypical Haemolytic Uraemic Syndrome (aHUS) are differently expressed in Tunisian and in Caucasian populations: CFH and CFHR1 polymorphisms in Tunisians. International Journal of Immunogenetics 2012;39:110-3. [DOI: 10.1111/j.1744-313x.2011.01071.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
106 Pangburn MK, Ferreira VP, Cortes C. Discrimination between host and pathogens by the complement system. Vaccine 2008;26 Suppl 8:I15-21. [PMID: 19388159 DOI: 10.1016/j.vaccine.2008.11.023] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 3.8] [Reference Citation Analysis]
107 Nozal P, Garrido S, Alba-Domínguez M, Espinosa L, Peña A, Córdoba SR, Sánchez-Corral P, López-Trascasa M. An ELISA assay with two monoclonal antibodies allows the estimation of free factor H and identifies patients with acquired deficiency of this complement regulator. Mol Immunol 2014;58:194-200. [PMID: 24378252 DOI: 10.1016/j.molimm.2013.11.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
108 Lachmann PJ. The amplification loop of the complement pathways. Adv Immunol 2009;104:115-49. [PMID: 20457117 DOI: 10.1016/S0065-2776(08)04004-2] [Cited by in Crossref: 138] [Cited by in F6Publishing: 77] [Article Influence: 10.6] [Reference Citation Analysis]
109 Rodríguez de Córdoba S, Harris CL, Morgan BP, Llorca O. Lessons from functional and structural analyses of disease-associated genetic variants in the complement alternative pathway. Biochim Biophys Acta 2011;1812:12-22. [PMID: 20837143 DOI: 10.1016/j.bbadis.2010.09.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
110 Ueda Y, Gullipalli D, Song WC. Modeling complement-driven diseases in transgenic mice: Values and limitations. Immunobiology 2016;221:1080-90. [PMID: 27371974 DOI: 10.1016/j.imbio.2016.06.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
111 Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, Novak J. Current Understanding of the Role of Complement in IgA Nephropathy. J Am Soc Nephrol. 2015;26:1503-1512. [PMID: 25694468 DOI: 10.1681/asn.2014101000] [Cited by in Crossref: 134] [Cited by in F6Publishing: 74] [Article Influence: 19.1] [Reference Citation Analysis]
112 Noris M, Brioschi S, Caprioli J, Todeschini M, Bresin E, Porrati F, Gamba S, Remuzzi G; International Registry of Recurrent and Familial HUS/TTP. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet. 2003;362:1542-1547. [PMID: 14615110 DOI: 10.1016/s0140-6736(03)14742-3] [Cited by in Crossref: 239] [Cited by in F6Publishing: 71] [Article Influence: 13.3] [Reference Citation Analysis]
113 Dragon-durey M, Frémeaux-bacchi V. Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. Springer Semin Immun 2005;27:359-74. [DOI: 10.1007/s00281-005-0003-2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
114 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrología (English Edition) 2015;35:421-47. [DOI: 10.1016/j.nefroe.2015.11.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
115 Valoti E, Alberti M, Tortajada A, Garcia-Fernandez J, Gastoldi S, Besso L, Bresin E, Remuzzi G, Rodriguez de Cordoba S, Noris M. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. J Am Soc Nephrol. 2015;26:209-219. [PMID: 24904082 DOI: 10.1681/asn.2013121339] [Cited by in Crossref: 59] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
116 Pickering MC, Cook HT. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 2008;151:210-30. [PMID: 18190458 DOI: 10.1111/j.1365-2249.2007.03574.x] [Cited by in Crossref: 130] [Cited by in F6Publishing: 111] [Article Influence: 9.3] [Reference Citation Analysis]
117 Koskinen AR, Tukiainen E, Arola J, Nordin A, Höckerstedt HK, Nilsson B, Isoniemi H, Jokiranta TS. Complement Activation During Liver Transplantation-Special Emphasis on Patients With Atypical Hemolytic Uremic Syndrome: Complement Activation in Liver Transplantation. American Journal of Transplantation 2011;11:1885-95. [DOI: 10.1111/j.1600-6143.2011.03612.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
118 Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 2006;176:1305-10. [PMID: 16424154 DOI: 10.4049/jimmunol.176.3.1305] [Cited by in Crossref: 288] [Cited by in F6Publishing: 271] [Article Influence: 18.0] [Reference Citation Analysis]
119 Leban N, Aloui S, Touati D, Lakhdhar R, Skhiri H, Lefranc G, Achour A, Elmay M, Lopez-Trascasa M, Sanchez-Corral P, Chibani J, Haj Khelil A. Atypical hemolytic uremic syndrome in the Tunisian population. Int Urol Nephrol 2011;43:559-64. [PMID: 20499172 DOI: 10.1007/s11255-010-9754-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
120 Heinen S, Józsi M, Hartmann A, Noris M, Remuzzi G, Skerka C, Zipfel PF. Hemolytic Uremic Syndrome: A Factor H Mutation (E1172Stop) Causes Defective Complement Control at the Surface of Endothelial Cells. JASN 2007;18:506-14. [DOI: 10.1681/asn.2006091069] [Cited by in Crossref: 42] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
121 Yenerel MN. Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management. Turk J Haematol 2014;31:216-25. [PMID: 25319590 DOI: 10.4274/tjh.2013.0374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
122 Józsi M, Oppermann M, Lambris JD, Zipfel PF. The C-terminus of complement factor H is essential for host cell protection. Mol Immunol 2007;44:2697-706. [PMID: 17208302 DOI: 10.1016/j.molimm.2006.12.001] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 4.9] [Reference Citation Analysis]
123 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2015;35:421-47. [PMID: 26456110 DOI: 10.1016/j.nefro.2015.07.005] [Cited by in Crossref: 88] [Cited by in F6Publishing: 63] [Article Influence: 12.6] [Reference Citation Analysis]
124 Sofat R, Mangione PP, Gallimore JR, Hakobyan S, Hughes TR, Shah T, Goodship T, D'Aiuto F, Langenberg C, Wareham N, Morgan BP, Pepys MB, Hingorani AD. Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay. J Immunol Methods 2013;390:63-73. [PMID: 23376722 DOI: 10.1016/j.jim.2013.01.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
125 Martínez-Barricarte R, Heurich M, Valdes-Cañedo F, Vazquez-Martul E, Torreira E, Montes T, Tortajada A, Pinto S, Lopez-Trascasa M, Morgan BP, Llorca O, Harris CL, Rodríguez de Córdoba S. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010;120:3702-12. [PMID: 20852386 DOI: 10.1172/JCI43343] [Cited by in Crossref: 163] [Cited by in F6Publishing: 83] [Article Influence: 13.6] [Reference Citation Analysis]
126 De Vriese AS, Sethi S, Van Praet J, Nath KA, Fervenza FC. Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach. J Am Soc Nephrol. 2015;26:2917-2929. [PMID: 26185203 DOI: 10.1681/asn.2015020184] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
127 Pangburn MK, Rawal N, Cortes C, Alam MN, Ferreira VP, Atkinson MA. Polyanion-induced self-association of complement factor H. J Immunol 2009;182:1061-8. [PMID: 19124749 DOI: 10.4049/jimmunol.182.2.1061] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
128 Pickering M, Cook HT. Complement and glomerular disease: new insights: . Current Opinion in Nephrology and Hypertension 2011;20:271-7. [DOI: 10.1097/mnh.0b013e328345848b] [Cited by in Crossref: 61] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
129 Csincsi ÁI, Szabó Z, Bánlaki Z, Uzonyi B, Cserhalmi M, Kárpáti É, Tortajada A, Caesar JJE, Prohászka Z, Jokiranta TS, Lea SM, Rodríguez de Córdoba S, Józsi M. FHR-1 Binds to C-Reactive Protein and Enhances Rather than Inhibits Complement Activation. J Immunol 2017;199:292-303. [PMID: 28533443 DOI: 10.4049/jimmunol.1600483] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
130 Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017;91:539-51. [PMID: 27989322 DOI: 10.1016/j.kint.2016.10.005] [Cited by in Crossref: 256] [Cited by in F6Publishing: 226] [Article Influence: 42.7] [Reference Citation Analysis]
131 Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, Remuzzi G, Strain L, Goodship TH. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant. 2006;6:1948-1952. [PMID: 16889549 DOI: 10.1111/j.1600-6143.2006.01375.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 5.9] [Reference Citation Analysis]
132 Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship TH, Remuzzi G, International Registry of Recurrent and Familial HUS/TTP. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol. 2006;1:88-99. [PMID: 17699195 DOI: 10.2215/cjn.00050505] [Cited by in Crossref: 174] [Cited by in F6Publishing: 55] [Article Influence: 10.2] [Reference Citation Analysis]
133 Abbas F, El Kossi M, Kim JJ, Shaheen IS, Sharma A, Halawa A. Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in de novo and recurrent diseases. World J Transplantation 2018; 8(6): 203-219 [PMID: 30370231 DOI: 10.5500/wjt.v8.i6.203] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
134 Parmeggiani F, Sorrentino FS, Romano MR, Costagliola C, Semeraro F, Incorvaia C, D’Angelo S, Perri P, De Nadai K, Bonomo Roversi E. Mechanism of inflammation in age-related macular degeneration: an up-to-date on genetic landmarks. Mediators Inflamm. 2013;2013:435607. [PMID: 24369445 DOI: 10.1155/2013/435607] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
135 Józsi M, Heinen S, Hartmann A, Ostrowicz CW, Hälbich S, Richter H, Kunert A, Licht C, Saunders RE, Perkins SJ, Zipfel PF, Skerka C. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. J Am Soc Nephrol 2006;17:170-7. [PMID: 16338962 DOI: 10.1681/ASN.2005080868] [Cited by in Crossref: 95] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
136 Cantsilieris S, Nelson BJ, Huddleston J, Baker C, Harshman L, Penewit K, Munson KM, Sorensen M, Welch AE, Dang V, Grassmann F, Richardson AJ, Guymer RH, Graves-Lindsay TA, Wilson RK, Weber BHF, Baird PN, Allikmets R, Eichler EE. Recurrent structural variation, clustered sites of selection, and disease risk for the complement factor H (CFH) gene family. Proc Natl Acad Sci U S A 2018;115:E4433-42. [PMID: 29686068 DOI: 10.1073/pnas.1717600115] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
137 Goicoechea de Jorge E, Tortajada A, García SP, Gastoldi S, Merinero HM, García-Fernández J, Arjona E, Cao M, Remuzzi G, Noris M, Rodríguez de Córdoba S. Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2018;29:240-9. [PMID: 28993505 DOI: 10.1681/ASN.2017050518] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
138 Tortajada A, Montes T, Martínez-Barricarte R, Morgan BP, Harris CL, de Córdoba SR. The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum Mol Genet 2009;18:3452-61. [PMID: 19549636 DOI: 10.1093/hmg/ddp289] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 7.1] [Reference Citation Analysis]
139 Almalki AH, Sadagah LF, Qureshi M, Maghrabi H, Algain A, Alsaeed A. Atypical hemolytic-uremic syndrome due to complement factor I mutation. World J Nephrol 2017; 6(6): 243-250 [PMID: 29226095 DOI: 10.5527/wjn.v6.i6.243] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
140 Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013;56:199-212. [PMID: 23810412 DOI: 10.1016/j.molimm.2013.05.224] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
141 Richards A, Goodship JA, Goodship TH. The genetics and pathogenesis of haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura: . Current Opinion in Nephrology and Hypertension 2002;11:431-5. [DOI: 10.1097/00041552-200207000-00010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
142 Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease. World J Transplantation 2018; 8(5): 122-141 [PMID: 30211021 DOI: 10.5500/wjt.v8.i5.122] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
143 Kavanagh D, Goodship TH. Atypical hemolytic uremic syndrome: . Current Opinion in Hematology 2010;17:432-8. [DOI: 10.1097/moh.0b013e32833cae86] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
144 Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, Bettoni S, Murer L, Fremeaux-bacchi V, Vivarelli M, Emma F, Daina E, Remuzzi G. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Molecular Immunology 2016;71:131-42. [DOI: 10.1016/j.molimm.2016.01.010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
145 Schmidt CQ, Slingsby FC, Richards A, Barlow PN. Production of biologically active complement factor H in therapeutically useful quantities. Protein Expr Purif 2011;76:254-63. [PMID: 21146613 DOI: 10.1016/j.pep.2010.12.002] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
146 Ferreira VP, Herbert AP, Cortés C, McKee KA, Blaum BS, Esswein ST, Uhrín D, Barlow PN, Pangburn MK, Kavanagh D. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 2009;182:7009-18. [PMID: 19454698 DOI: 10.4049/jimmunol.0804031] [Cited by in Crossref: 122] [Cited by in F6Publishing: 123] [Article Influence: 9.4] [Reference Citation Analysis]
147 Perkins SJ, Goodship TH. Molecular modelling of the C-terminal domains of factor H of human complement: a correlation between haemolytic uraemic syndrome and a predicted heparin binding site. Journal of Molecular Biology 2002;316:217-24. [DOI: 10.1006/jmbi.2001.5337] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 2.7] [Reference Citation Analysis]
148 Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, López-Trascasa M, Sánchez-Corral P, Morgan BP, Rodríguez de Córdoba S. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA. 2007;104:240-245. [PMID: 17182750 DOI: 10.1073/pnas.0603420103] [Cited by in Crossref: 330] [Cited by in F6Publishing: 289] [Article Influence: 20.6] [Reference Citation Analysis]
149 Hirt-Minkowski P, Schaub S, Mayr M, Schifferli JA, Dickenmann M, Frémeaux-Bacchi V, Steiger J. Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option? Nephrol Dial Transplant 2009;24:3548-51. [PMID: 19633317 DOI: 10.1093/ndt/gfp377] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
150 Saunders RE, Abarrategui-Garrido C, Frémeaux-Bacchi V, Goicoechea de Jorge E, Goodship TH, López Trascasa M, Noris M, Ponce Castro IM, Remuzzi G, Rodríguez de Córdoba S, Sánchez-Corral P, Skerka C, Zipfel PF, Perkins SJ. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat 2007;28:222-34. [PMID: 17089378 DOI: 10.1002/humu.20435] [Cited by in Crossref: 127] [Cited by in F6Publishing: 114] [Article Influence: 8.5] [Reference Citation Analysis]
151 Hellwage J, Jokiranta TS, Friese MA, Wolk TU, Kampen E, Zipfel PF, Meri S. Complement C3b/C3d and Cell Surface Polyanions Are Recognized by Overlapping Binding Sites on the Most Carboxyl-Terminal Domain of Complement Factor H. J Immunol 2002;169:6935-44. [DOI: 10.4049/jimmunol.169.12.6935] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 4.6] [Reference Citation Analysis]
152 Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26:41-57. [PMID: 20556434 DOI: 10.1007/s00467-010-1556-4] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
153 Boon CJ, Klevering BJ, Hoyng CB, Zonneveld-Vrieling MN, Nabuurs SB, Blokland E, Cremers FP, den Hollander AI. Basal laminar drusen caused by compound heterozygous variants in the CFH gene. Am J Hum Genet 2008;82:516-23. [PMID: 18252232 DOI: 10.1016/j.ajhg.2007.11.007] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 4.7] [Reference Citation Analysis]
154 Xu B, Kang Y, Du Y, Guo W, Zhu L, Zhang H. Atypical Hemolytic Uremic Syndrome-Associated FHR1 Isoform FHR1*B Enhances Complement Activation and Inflammation. Front Immunol 2022;13:755694. [DOI: 10.3389/fimmu.2022.755694] [Reference Citation Analysis]
155 Tecklenborg J, Clayton D, Siebert S, Coley SM. The role of the immune system in kidney disease. Clin Exp Immunol 2018;192:142-50. [PMID: 29453850 DOI: 10.1111/cei.13119] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
156 Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267-1279. [PMID: 16621965 DOI: 10.1182/blood-2005-10-007252] [Cited by in Crossref: 499] [Cited by in F6Publishing: 410] [Article Influence: 31.2] [Reference Citation Analysis]
157 Fremeaux-Bacchi V, Moulton EA, Kavanagh D, Dragon-Durey MA, Blouin J, Caudy A, Arzouk N, Cleper R, Francois M, Guest G. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2006;17:2017-2025. [PMID: 16762990 DOI: 10.1681/asn.2005101051] [Cited by in Crossref: 177] [Cited by in F6Publishing: 77] [Article Influence: 11.1] [Reference Citation Analysis]
158 Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Frémeaux-Bacchi V. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:555-63. [PMID: 15590760 DOI: 10.1681/ASN.2004050380] [Cited by in Crossref: 362] [Cited by in F6Publishing: 135] [Article Influence: 20.1] [Reference Citation Analysis]
159 Abarrategui-Garrido C, Melgosa M, Peña-Carrión A, de Jorge EG, de Córdoba SR, López-Trascasa M, Sánchez-Corral P. Mutations in proteins of the alternative pathway of complement and the pathogenesis of atypical hemolytic uremic syndrome. Am J Kidney Dis 2008;52:171-80. [PMID: 18423815 DOI: 10.1053/j.ajkd.2008.01.026] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
160 Neumann HP, Salzmann M, Bohnert-Iwan B, Mannuelian T, Skerka C, Lenk D, Bender BU, Cybulla M, Riegler P, Königsrainer A, Neyer U, Bock A, Widmer U, Male DA, Franke G, Zipfel PF. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet 2003;40:676-81. [PMID: 12960213 DOI: 10.1136/jmg.40.9.676] [Cited by in Crossref: 153] [Cited by in F6Publishing: 147] [Article Influence: 8.1] [Reference Citation Analysis]
161 Cooper M, McGraw ME, Unsworth DJ, Mathieson P. Familial mesangio-capillary glomerulonephritis with initial presentation as haemolytic uraemic syndrome. Nephrol Dial Transplant 2004;19:230-3. [PMID: 14671063 DOI: 10.1093/ndt/gfg470] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
162 Klein R, Knudtson MD, Lee KE, Klein BE. Serum cystatin C level, kidney disease markers, and incidence of age-related macular degeneration: the Beaver Dam Eye Study. Arch Ophthalmol 2009;127:193-9. [PMID: 19204238 DOI: 10.1001/archophthalmol.2008.551] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
163 Boon CJ, van de Ven JP, Hoyng CB, den Hollander AI, Klevering BJ. Cuticular drusen: Stars in the sky. Progress in Retinal and Eye Research 2013;37:90-113. [DOI: 10.1016/j.preteyeres.2013.08.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
164 Blom AM, Mark L, Spiller OB. Viral Heparin-Binding Complement Inhibitors – A Recurring Theme. In: Lambris JD, editor. Current Topics in Innate Immunity. New York: Springer; 2007. pp. 105-25. [DOI: 10.1007/978-0-387-71767-8_9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
165 Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Würzner R, Jungraithmayr T; German-Austrian HUS Study Group. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2013;8:407-15. [PMID: 23243267 DOI: 10.2215/CJN.01260212] [Cited by in Crossref: 80] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
166 Sartain SE, Turner NA, Moake JL. TNF Regulates Essential Alternative Complement Pathway Components and Impairs Activation of Protein C in Human Glomerular Endothelial Cells. J I 2016;196:832-45. [DOI: 10.4049/jimmunol.1500960] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
167 Ermini L, Goodship TH, Strain L, Weale ME, Sacks SH, Cordell HJ, Fremeaux-Bacchi V, Sheerin NS. Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Mol Immunol 2012;49:640-8. [PMID: 22153652 DOI: 10.1016/j.molimm.2011.11.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
168 Ueda Y, Miwa T, Gullipalli D, Sato S, Ito D, Kim H, Palmer M, Song WC. Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia. J Am Soc Nephrol 2018;29:1928-37. [PMID: 29858280 DOI: 10.1681/ASN.2017121244] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
169 Berger SP, Roos A, Daha MR. Complement and the kidney: what the nephrologist needs to know in 2006? Nephrol Dial Transplant 2005;20:2613-9. [PMID: 16204271 DOI: 10.1093/ndt/gfi166] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
170 Ren Z, Perkins SJ, Love-Gregory L, Atkinson JP, Java A. Clinicopathologic Implications of Complement Genetic Variants in Kidney Transplantation. Front Med (Lausanne) 2021;8:775280. [PMID: 34912830 DOI: 10.3389/fmed.2021.775280] [Reference Citation Analysis]
171 Oppermann M, Manuelian T, Józsi M, Brandt E, Jokiranta TS, Heinen S, Meri S, Skerka C, Götze O, Zipfel PF. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol 2006;144:342-52. [PMID: 16634809 DOI: 10.1111/j.1365-2249.2006.03071.x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 118] [Article Influence: 7.6] [Reference Citation Analysis]
172 Tortajada A, Pinto S, Martínez-Ara J, López-Trascasa M, Sánchez-Corral P, de Córdoba SR. Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance. Kidney Int 2012;81:56-63. [PMID: 21881555 DOI: 10.1038/ki.2011.291] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
173 Muff-Luett M, Nester CM. The Genetics of Ultra-Rare Renal Disease. J Pediatr Genet 2016;5:33-42. [PMID: 27617140 DOI: 10.1055/s-0036-1572515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
174 Herbert AP, Uhrín D, Lyon M, Pangburn MK, Barlow PN. Disease-associated sequence variations congregate in a polyanion recognition patch on human factor H revealed in three-dimensional structure. J Biol Chem 2006;281:16512-20. [PMID: 16533809 DOI: 10.1074/jbc.M513611200] [Cited by in Crossref: 76] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
175 Zipfel PF, Skerka C. Complement dysfunction in hemolytic uremic syndrome. Curr Opin Rheumatol 2006;18:548-55. [PMID: 16896298 DOI: 10.1097/01.bor.0000240370.47336.ae] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
176 Hegasy GA, Manuelian T, Hogasen K, Jansen JH, Zipfel PF. The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion. Am J Pathol 2002;161:2027-34. [PMID: 12466119 DOI: 10.1016/S0002-9440(10)64481-1] [Cited by in Crossref: 60] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
177 Martinez-Barricarte R, Pianetti G, Gautard R, Misselwitz J, Strain L, Fremeaux-Bacchi V, Skerka C, Zipfel PF, Goodship T, Noris M, Remuzzi G, de Cordoba SR; European Working Party on the Genetics of HUS. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2008;19:639-46. [PMID: 18235085 DOI: 10.1681/ASN.2007080923] [Cited by in Crossref: 67] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
178 Cheong HI, Lee BS, Kang HG, Hahn H, Suh KS, Ha IS, Choi Y. Attempted treatment of factor H deficiency by liver transplantation. Pediatr Nephrol 2004;19:454-8. [PMID: 14986080 DOI: 10.1007/s00467-003-1371-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 3.4] [Reference Citation Analysis]
179 Savige J, Amos L, Ierino F, Mack HG, Symons RC, Hughes P, Nicholls K, Colville D. Retinal disease in the C3 glomerulopathies and the risk of impaired vision. Ophthalmic Genet 2016;37:369-76. [PMID: 26915021 DOI: 10.3109/13816810.2015.1101777] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
180 Kaare M, Seitsonen S, Jarvela I, Meri S, Laivuori H. Complement factor H variant Y402H is not a risk factor for preeclampsia in the Finnish population. Hypertens Pregnancy 2008;27:328-36. [PMID: 19003634 DOI: 10.1080/10641950801955691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
181 Filippone EJ, Newman ED, Li L, Gulati R, Farber JL. Thrombotic Microangiopathy, an Unusual Form of Monoclonal Gammopathy of Renal Significance: Report of 3 Cases and Literature Review. Front Immunol 2021;12:780107. [PMID: 34858436 DOI: 10.3389/fimmu.2021.780107] [Reference Citation Analysis]
182 Kavanagh D, Richards A, Noris M, Hauhart R, Liszewski MK, Karpman D, Goodship JA, Fremeaux-Bacchi V, Remuzzi G, Goodship TH, Atkinson JP. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol 2008;45:95-105. [PMID: 17597211 DOI: 10.1016/j.molimm.2007.05.004] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 6.8] [Reference Citation Analysis]
183 Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33:508-530. [PMID: 24161037 DOI: 10.1016/j.semnephrol.2013.08.003] [Cited by in Crossref: 204] [Cited by in F6Publishing: 156] [Article Influence: 25.5] [Reference Citation Analysis]
184 Hageman GS, Hancox LS, Taiber AJ, Gehrs KM, Anderson DH, Johnson LV, Radeke MJ, Kavanagh D, Richards A, Atkinson J, Meri S, Bergeron J, Zernant J, Merriam J, Gold B, Allikmets R, Dean M. Extended haplotypes in the complement factor H ( CFH ) and CFH‐related ( CFHR ) family of genes protect against age‐related macular degeneration: Characterization, ethnic distribution and evolutionary implications. Annals of Medicine 2009;38:592-604. [DOI: 10.1080/07853890601097030] [Cited by in Crossref: 166] [Cited by in F6Publishing: 72] [Article Influence: 12.8] [Reference Citation Analysis]
185 Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods. 2011;365:8-26. [PMID: 21215749 DOI: 10.1016/j.jim.2010.12.020] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 9.8] [Reference Citation Analysis]
186 Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol. 2013;24:475-486. [PMID: 23431077 DOI: 10.1681/asn.2012090884] [Cited by in Crossref: 231] [Cited by in F6Publishing: 110] [Article Influence: 25.7] [Reference Citation Analysis]
187 Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, Jozsi M, Neumann HP, Remuzzi G, Zipfel PF. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest. 2003;111:1181-1190. [PMID: 12697737 DOI: 10.1172/jci16651] [Cited by in Crossref: 217] [Cited by in F6Publishing: 113] [Article Influence: 11.4] [Reference Citation Analysis]
188 Tortajada A, Gutiérrez E, Goicoechea de Jorge E, Anter J, Segarra A, Espinosa M, Blasco M, Roman E, Marco H, Quintana LF, Gutiérrez J, Pinto S, Lopez-trascasa M, Praga M, Rodriguez de Córdoba S. Elevated factor H–related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy. Kidney International 2017;92:953-63. [DOI: 10.1016/j.kint.2017.03.041] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
189 Davin JC, Olie KH, Verlaak R, Horuz F, Florquin S, Weening JJ, Groothoff JW, Strain L, Goodship TH. Complement factor H-associated atypical hemolytic uremic syndrome in monozygotic twins: concordant presentation, discordant response to treatment. Am J Kidney Dis 2006;47:e27-30. [PMID: 16431247 DOI: 10.1053/j.ajkd.2005.11.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
190 Martínez-Barricarte R, Goicoechea de Jorge E, Montes T, Layana AG, Rodríguez de Córdoba S. Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population. Clin Exp Immunol 2009;155:59-64. [PMID: 19076829 DOI: 10.1111/j.1365-2249.2008.03798.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
191 Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship TH, Atkinson JP. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008;111:624-32. [PMID: 17914026 DOI: 10.1182/blood-2007-04-084533] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 6.8] [Reference Citation Analysis]
192 Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:345-357. [PMID: 19625716 DOI: 10.1056/nejmoa0810739] [Cited by in Crossref: 368] [Cited by in F6Publishing: 153] [Article Influence: 28.3] [Reference Citation Analysis]
193 Schejbel L, Schmidt IM, Kirchhoff M, Andersen CB, Marquart HV, Zipfel P, Garred P. Complement factor H deficiency and endocapillary glomerulonephritis due to paternal isodisomy and a novel factor H mutation. Genes Immun. 2011;12:90-99. [PMID: 21270828 DOI: 10.1038/gene.2010.63] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
194 Fujimura Y. Is Upshaw-Schulman syndrome congenital thrombotic thrombocytopenic purpura or hemolytic-uremic syndrome? Yes to both. J Thromb Haemost 2003;1:2457-8. [DOI: 10.1046/j.1538-7836.2003.0468f.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
195 de Córdoba SR, de Jorge EG. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol 2008;151:1-13. [PMID: 18081690 DOI: 10.1111/j.1365-2249.2007.03552.x] [Cited by in Crossref: 192] [Cited by in F6Publishing: 184] [Article Influence: 13.7] [Reference Citation Analysis]
196 Kavanagh D, Burgess R, Spitzer D, Richards A, Diaz-Torres ML, Goodship JA, Hourcade DE, Atkinson JP, Goodship TH. The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation. Mol Immunol 2007;44:3162-7. [PMID: 17368771 DOI: 10.1016/j.molimm.2007.01.036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
197 de Córdoba SR. Complement genetics and susceptibility to inflammatory disease. Lessons from genotype-phenotype correlations. Immunobiology 2016;221:709-14. [PMID: 26004345 DOI: 10.1016/j.imbio.2015.05.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
198 Morgan HP, Schmidt CQ, Guariento M, Blaum BS, Gillespie D, Herbert AP, Kavanagh D, Mertens HD, Svergun DI, Johansson CM. Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol. 2011;18:463-470. [PMID: 21317894 DOI: 10.1038/nsmb.2018] [Cited by in Crossref: 171] [Cited by in F6Publishing: 162] [Article Influence: 15.5] [Reference Citation Analysis]
199 Kavanagh D, Kemp EJ, Mayland E, Winney RJ, Duffield JS, Warwick G, Richards A, Ward R, Goodship JA, Goodship TH. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16:2150-2155. [PMID: 15917334 DOI: 10.1681/asn.2005010103] [Cited by in Crossref: 190] [Cited by in F6Publishing: 69] [Article Influence: 11.2] [Reference Citation Analysis]
200 Gerber A, Kirchhoff-Moradpour AH, Obieglo S, Brandis M, Kirschfink M, Zipfel PF, Goodship JA, Zimmerhackl LB. Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality. Pediatr Nephrol 2003;18:952-5. [PMID: 12836093 DOI: 10.1007/s00467-003-1192-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
201 Smith-Jackson K, Yang Y, Denton H, Pappworth IY, Cooke K, Barlow PN, Atkinson JP, Liszewski MK, Pickering MC, Kavanagh D, Cook HT, Marchbank KJ. Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice. J Clin Invest 2019;129:1061-75. [PMID: 30714990 DOI: 10.1172/JCI99296] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]